Medicare Enrolled

Dr. Howard Cheng, M.D.

Hematology & Oncology · Laguna Hills, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
24953 PASEO DE VALENCIA, Laguna Hills, CA 92653
9497708168
In practice since 2005 (20 years)
NPI: 1366435299 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Cheng from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Cheng? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Cheng

Dr. Howard Cheng is a hematology & oncology specialist in Laguna Hills, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Cheng performed 34,770 Medicare services across 1,588 unique beneficiaries.

Between the years covered by Open Payments, Dr. Cheng received a total of $4,449 from 36 pharmaceutical and/or device companies across 209 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Cheng is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 18% volume in CA $4,449 industry payments

Medicare Practice Summary

Medicare Utilization ↗
34,770
Medicare services
Top 18% in CA for hematology & oncology
1,588
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,738 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Iron infusion (Feraheme)
An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis.
23,460 $0 $4
Epoetin alfa injection (Retacrit) for anemia
An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units.
4,400 $6 $25
Complete blood count (CBC) with differential
An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells.
1,710 $8 $53
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
1,476 $8 $18
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
979 $101 $207
Dexamethasone injection (steroid)
An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram.
948 $0 $5
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
531 $149 $306
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
382 $12 $48
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
225 $67 $148
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
189 $119 $502
Additional sequential IV infusion, 1 hour or less
This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less.
183 $26 $100
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
109 $59 $178
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
71 $93 $270
New patient office visit, complex (60-74 min) 50 $179 $374
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
24 $132 $320
Irrigation of implanted venous access device
This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids.
22 $22 $100
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
11 $72 $171
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
68.9% high complexity
17.1% medium
14.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$4,449
Total received (2018-2024)
Avg $636/year across 7 years
Top 45% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
36
Companies
209
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,972 (89.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$477 (10.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$893
2023
$515
2022
$153
2021
$366
2020
$474
2019
$1,092
2018
$955

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$379
INTUITIVE SURGICAL, INC.
$132
Novartis Pharmaceuticals Corporation
$83
AstraZeneca Pharmaceuticals LP
$79
Janssen Pharmaceuticals, Inc
$58
Coherus Biosciences Inc.
$35
Alexion Pharmaceuticals, Inc.
$31
Tempus AI, Inc
$29
GENZYME CORPORATION
$24
E.R. Squibb & Sons, L.L.C.
$22
EMD Serono, Inc.
$21
Top 3 companies account for 66.5% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$821
Novartis Pharmaceuticals Corporation
$793
Janssen Biotech, Inc.
$653
Amgen Inc.
$448
E.R. Squibb & Sons, L.L.C.
$226
Bayer Healthcare Pharmaceuticals Inc.
$150
Pharmacyclics LLC, An AbbVie Company
$133
INTUITIVE SURGICAL, INC.
$132
PFIZER INC.
$113
Merck Sharp & Dohme Corporation
$113
Janssen Pharmaceuticals, Inc
$83
EMD Serono, Inc.
$68
Genentech USA, Inc.
$50
Coherus Biosciences Inc.
$50
Astellas Pharma US Inc
$48
PUMA BIOTECHNOLOGY, INC.
$44
Incyte Corporation
$44
Seattle Genetics, Inc.
$40
Helsinn Therapeutics (U.S.), Inc.
$38
Gilead Sciences, Inc.
$35
Celgene Corporation
$33
Lilly USA, LLC
$32
Alexion Pharmaceuticals, Inc.
$31
Tempus AI, Inc
$29
Exelixis Inc.
$26
AMAG Pharmaceuticals, Inc.
$25
GENZYME CORPORATION
$24
Myovant Sciences Inc.
$24
Merck Sharp & Dohme LLC
$23
Rigel Pharmaceuticals, Inc.
$22
AbbVie, Inc.
$22
Bayer HealthCare Pharmaceuticals Inc.
$20
Daiichi Sankyo Inc.
$16
Otsuka America Pharmaceutical, Inc.
$14
AbbVie Inc.
$13
MEDIVATION FIELD SOLUTIONS LLC
$13
Top 3 companies account for 51.0% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · Alecensa · Balversa · Bavencio · CALQUENCE · Cabometyx · DARZALEX · Da Vinci Surgical System · EMPLICITI · ERBITUX · ERLEADA · Erleada · FASLODEX · FERAHEME · Fabhalta · IMBRUVICA · IMFINZI · INJECTAFER · Imbruvica · JADENU · JAKAFI · KEYTRUDA · KISQALI · Kerendia · Kyprolis · LUMAKRAS · LYNPARZA · MEKINIST · MYLOTARG · NERLYNX · Nexavar · Nplate · OPDIVO · OPDUALAG · ORGOVYX · PIQRAY · PLUVICTO · PROMACTA · Pomalyst · REBLOZYL · RYDAPT · SARCLISA · SPRYCEL · SUTENT · TAGRISSO · TASIGNA · TECENTRIQ · Tavalisse · ULTOMIRIS · Udenyca · VENCLEXTA · Vectibix · Venclexta · XARELTO · XTANDI · ZYKADIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in Laguna Hills?
Compare hematology & oncology specialists in the Laguna Hills area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
129
Per 100K population
4.1
County median income
$113,702
Nearest hospital
MEMORIALCARE SADDLEBACK MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Cheng is a mixed practice specialist, with above-average Medicare volume (top 18% in CA), with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Cheng experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Cheng performed 23,460 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Cheng receive payments from pharmaceutical companies?
Yes. Dr. Cheng received a total of $4,449 from 36 companies across 209 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Cheng's costs compare to other hematology & oncology specialists in Laguna Hills?
Dr. Cheng's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Cheng) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →